Amendments to related matters that OBI forfeits part of subscription rights of Obigen’s cash capital increase and distributes the rights to its shareholders

1.Date of occurrence of the event:2022/11/28 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios: Not applicable 5.Cause of occurrence: …

OBI sets target date of distribution of other benefits from forfeiture of subscription rights to its shareholders for Obigen’s 2022 cash capital increase

1.Date of occurrence of the event:2022/11/24 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence: To be …

The Company’s BOD resolved to forfeit part of subscription rights of Obigen’s cash capital increase and distribute the rights to its shareholders

1.Date of occurrence of the event:2022/11/24 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence:To share the …

The Company correct the information on monetary loans extended to others filed on September and October 2022

1.Date of occurrence of the event:2022/11/23 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter ”headoffice” or ”subsidiaries”): OBI Pharma Australia Pty Ltd (The wholly owned subsidiary of …

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by TFDA

1.Date of occurrence of the event:2022/11/14 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences (hereinafter referred to as APBio). …

Announcement on behalf of APBio’s resolution to lift non-competition restrictions for directors at 2022 extraordinary Shareholders’ Meeting

1.Date of the shareholders’ meeting resolution:2022/11/09 2.Name and title of the managerial officer with permission to engage in competitive conduct: Director Frank Chen Director Jeng Her Director Ming-Tain Lai Director …

Announcement on behalf of AP Biosciences. regarding its by-election of director and supervisor at 2022 first extraordinary General Shareholders’ Meeting

1.Date of occurrence of the change:2022/11/09 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor):natural-person director and natural-person supervisor 3.Title and name …

Announcement on behalf of AP Biosciences’ important resolutions of 2022 first extraordinary General Shareholders’ Meeting

1.Date of the special shareholders’ meeting:2022/11/09 2.Important resolutions: (1)Matters for Discussion: A.Amendments to the Company’s “Rules for Scope of Duties and Execution of Power of Supervisors” B.Amendments to the Company’s …

Announcement of the Consolidated Financial Statements for the third quarter of 2022 were approved by the Board of Directors

1.Date of the board of directors submitted or approved:2022/11/04 2.Date of the audit committee approved:2022/11/04 3.Start and end dates of financial reports or unaudited financial information of the reporting period …

Announcement on behalf of AP Biosciences that the BOD resolved to convene 2022 first extraordinary General Shareholders’ Meeting

1.Date of the board of directors resolution:2022/10/18 2.Extraordinary shareholders’ meeting date:2022/11/09 3.Extraordinary shareholders’ meeting location: Building A. 2F., No. 19-10, Sanchong Rd., Nangang Dist., Taipei City (Conference room located on …